HIF1A and breast carcinoma: For example, upregulation of p53 pro-apoptotic protein inhibitor can lead to drug resistance in leukemia, breast cancer, hepatocellular carcinoma, ovarian cancer, renal malignancies.[10] Since HIF-1α plays a central role in aerobic glycolysis and is involved in the development of chemotherapeutic drug resistance, then anti-HIF-1α chemotherapeutic drugs may have great therapeutic potential for drug-resistant individuals in chemotherapeutic drug development and clinical trials.